Bioengineering
-
In Vitro Safety “Clinical Trial” of the Cardiac Liability of Hydroxychloroquine and Azithromycin as COVID19 Polytherapy
This article has 7 authors:Reviewed by ScreenIT
-
Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike
This article has 16 authors:Reviewed by ScreenIT
-
A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies
This article has 4 authors:Reviewed by ScreenIT
-
Engineering, production and characterization of Spike and Nucleocapsid structural proteins of SARS–CoV-2 in Nicotiana benthamiana as vaccine candidates against COVID-19
This article has 8 authors:Reviewed by ScreenIT
-
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
This article has 41 authors:Reviewed by ScreenIT
-
Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells
This article has 8 authors:Reviewed by ScreenIT
-
Rapid generation of circulating and mucosal decoy ACE2 using mRNA nanotherapeutics for the potential treatment of SARS-CoV-2
This article has 5 authors:Reviewed by ScreenIT
-
High affinity modified ACE2 receptors protect from SARS-CoV-2 infection in hamsters
This article has 18 authors:Reviewed by ScreenIT
-
In vitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2
This article has 3 authors:Reviewed by ScreenIT
-
EXPERIMENTAL INVESTIGATION OF PULSE STERILIZATION OF VIRAL INFECTION
This article has 7 authors:Reviewed by ScreenIT